KR20140088199A - 경피 전달 조성물 및 방법 - Google Patents

경피 전달 조성물 및 방법 Download PDF

Info

Publication number
KR20140088199A
KR20140088199A KR1020147014699A KR20147014699A KR20140088199A KR 20140088199 A KR20140088199 A KR 20140088199A KR 1020147014699 A KR1020147014699 A KR 1020147014699A KR 20147014699 A KR20147014699 A KR 20147014699A KR 20140088199 A KR20140088199 A KR 20140088199A
Authority
KR
South Korea
Prior art keywords
composition
antioxidant
progestin
pvp
psa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147014699A
Other languages
English (en)
Korean (ko)
Inventor
찰스 지. 아놀드
아기스 키도니우스
토마스 엠. 로시
알프레드 에프. 알토마리
Original Assignee
애자일 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 애자일 쎄라퓨틱스, 인크. filed Critical 애자일 쎄라퓨틱스, 인크.
Publication of KR20140088199A publication Critical patent/KR20140088199A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147014699A 2011-11-04 2012-11-02 경피 전달 조성물 및 방법 Ceased KR20140088199A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161555546P 2011-11-04 2011-11-04
US61/555,546 2011-11-04
US201261645778P 2012-05-11 2012-05-11
US61/645,778 2012-05-11
PCT/US2012/063314 WO2013067346A1 (en) 2011-11-04 2012-11-02 Dermal delivery compositions and methods

Publications (1)

Publication Number Publication Date
KR20140088199A true KR20140088199A (ko) 2014-07-09

Family

ID=47278507

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147014699A Ceased KR20140088199A (ko) 2011-11-04 2012-11-02 경피 전달 조성물 및 방법

Country Status (17)

Country Link
US (3) US9364487B2 (cg-RX-API-DMAC7.html)
EP (1) EP2773333B1 (cg-RX-API-DMAC7.html)
JP (1) JP6316749B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140088199A (cg-RX-API-DMAC7.html)
CN (1) CN103957899A (cg-RX-API-DMAC7.html)
AU (1) AU2012332254B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014010670A2 (cg-RX-API-DMAC7.html)
CA (1) CA2854164C (cg-RX-API-DMAC7.html)
EA (1) EA026664B1 (cg-RX-API-DMAC7.html)
ES (1) ES2762460T3 (cg-RX-API-DMAC7.html)
HK (1) HK1200317A1 (cg-RX-API-DMAC7.html)
IL (1) IL232258A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03247A (cg-RX-API-DMAC7.html)
MX (1) MX353713B (cg-RX-API-DMAC7.html)
PH (1) PH12014501000A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013067346A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201402988B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
GB2521632B (en) * 2013-12-23 2020-12-16 Linscott Goode Steven Vermin control compositions
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN111295202B (zh) * 2017-10-30 2022-07-08 科研制药株式会社 治疗甲癣的外用制剂
JP7220473B2 (ja) * 2017-10-30 2023-02-10 帝國製薬株式会社 経皮投与製剤
US20210347978A1 (en) * 2018-09-19 2021-11-11 Isp Investments Llc Peroxide stable polymer composition and process for its preparation and applications thereof
CN113455506A (zh) * 2021-06-29 2021-10-01 无锡宏霸医疗科技有限公司 一种适用于日化产品的水相除臭去味剂及其制备方法
CN114259498B (zh) * 2021-12-02 2023-04-28 南通联亚药业股份有限公司 一种包含去氧孕烯和炔雌醇的药物组合物及其制备方法和应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
FR2739031B1 (fr) * 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
DE19700913C2 (de) * 1997-01-14 2001-01-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Hormonen
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
KR20010112479A (ko) * 1999-07-01 2001-12-20 나까도미 히로다카 경피흡수 첩부제
US7384650B2 (en) * 1999-11-24 2008-06-10 Agile Therapeutics, Inc. Skin permeation enhancement composition for transdermal hormone delivery system
US7045145B1 (en) 1999-11-24 2006-05-16 Agile Therapeutics, Inc. Transdermal contraceptive delivery system and process
ES2338860T3 (es) * 1999-11-24 2010-05-13 Agile Therapeutics, Inc. Sistema y procedimiento de administracion de anticonceptivos transdermica mejorado.
DE50115609D1 (de) * 2000-02-17 2010-10-14 Basf Se Wässrige Dispersion wasserunlöslicher organischer UV-Filtersubstanzen
JP4422430B2 (ja) * 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
US20060121102A1 (en) * 2004-09-27 2006-06-08 Chia-Ming Chiang Transdermal systems for the delivery of estrogens and progestins
AU2006236564B2 (en) * 2005-04-15 2011-02-17 Besins Healthcare Luxembourg S.A.R.L. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
EA015155B1 (ru) * 2005-05-26 2011-06-30 Тева Вуменс Хелс, Инк. Дозированные формы для перорального применения, содержащие прогестерон, и способы их изготовления и использования
US10137135B2 (en) * 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
DE102006050558B4 (de) * 2006-10-26 2009-03-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System enthaltend Norelgestromin zur Kontrazeption und Hormonsubstitution
EP2086550A2 (en) * 2006-11-29 2009-08-12 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
US20100178323A1 (en) 2007-07-10 2010-07-15 Agis Kydonieus Dermal Delivery Device
EP2167001A4 (en) 2007-07-10 2012-10-31 Agile Therapeutics Inc DEVICE FOR THE DERIVED ULTRASONIC WELDING
CN101801321B (zh) 2007-07-10 2014-07-02 敏捷治疗公司 原位密封的经皮输送装置
US20090285893A1 (en) * 2008-05-19 2009-11-19 The Procter & Gamble Company Treatment of heart failure in women
US9198920B2 (en) * 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones

Also Published As

Publication number Publication date
EP2773333A1 (en) 2014-09-10
ZA201402988B (en) 2015-11-25
CN103957899A (zh) 2014-07-30
EA026664B1 (ru) 2017-05-31
US20160250226A1 (en) 2016-09-01
JP6316749B2 (ja) 2018-04-25
CA2854164A1 (en) 2013-05-10
MX2014005294A (es) 2014-09-22
AU2012332254B2 (en) 2017-06-22
IL232258A0 (en) 2014-06-30
EA201400543A1 (ru) 2014-09-30
NZ624117A (en) 2016-02-26
JP2014532719A (ja) 2014-12-08
AU2012332254A1 (en) 2014-05-15
EP2773333B1 (en) 2019-10-02
US20180325916A1 (en) 2018-11-15
HK1201152A1 (en) 2015-08-28
US9364487B2 (en) 2016-06-14
BR112014010670A2 (pt) 2017-05-09
WO2013067346A1 (en) 2013-05-10
CA2854164C (en) 2021-04-13
ES2762460T3 (es) 2020-05-25
IN2014DN03247A (cg-RX-API-DMAC7.html) 2015-05-22
PH12014501000A1 (en) 2014-06-09
HK1200317A1 (en) 2015-08-07
MX353713B (es) 2018-01-24
US20130116222A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
US9364487B2 (en) Dermal delivery compositions and methods
US9844515B2 (en) Transdermal therapeutic system comprising buprenorphine
CA2222133C (en) Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
CZ20013763A3 (cs) Transdermální terapeutický systém s neutralizovaným akrylátovým adhezivním lepidlem
US7056528B1 (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
JP2003530354A (ja) 経皮製剤において高親油性有効成分の透過促進剤として利用するための組成物
CN116036055A (zh) 一种含甲磺酸雷沙吉兰的透皮贴剂及其制备方法
JP6345120B2 (ja) 経皮ホルモン送達
CN1187042C (zh) 含甾族化合物的硬膏剂,其制备方法及其应用
JP2003063955A (ja) 経皮吸収型貼付剤
NZ624117B2 (en) Dermal delivery compositions and methods
HK1201152B (en) Dermal delivery compositions and methods
JP6864968B2 (ja) 貼付剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140530

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171102

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181126

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190325

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20181126

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I